Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=89 Pre-operative Rehabilitation for Reduction of Hospitalization After Coronary Bypass and Valvular Surgery.
Patients Waiting for Coronary Artery Bypass Graft Surgery · Patients Waiting for Aortic Valve Repair or Replacement · Patients Waiting for Mitral Valve Repair or Replacement
Primary: Proportion of Patients With Hospital Length of Stay Greater Than 7 Days. — 20; 16 Participants
Phase 4 N=91 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
Arteriosclerosis of Coronary Artery Bypass Graft
Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts
N/A N=453 Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery
Cardiovascular Diseases · Coronary Disease · Heart Diseases
Primary: Generic Mental Health-Related Quality of Life — 50.0; 46.2; 57.2 units on a scale
Phase 4 N=500 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass · Antiplatelet Agents
Primary: The Patency of Saphenous Vein Grafts — 76.5; 88.7; 82.8 percentage of patent SV grafts
Phase 2 N=11 AZD8601 Study in CABG Patients
Heart Failure
Primary: Number of Subjects With Adverse Events — 7; 4 Participants
Phase 3 N=2,136 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
Cardiovascular Diseases · Coronary Disease · Heart Failure, Congestive
Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12
N/A N=301 Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61
Phase 4 N=411 On Versus Off Pump Myocardial Revascularization Study
Coronary Artery Disease
Primary: Number of Patients With Post-operative Combined Endpoint (i.e. With One or More of the Following) — 13; 26 participants
N/A N=733 Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery
Cardiovascular Disease · Coronary Artery Disease
Primary: To Compare 1-year Angiographic Patency of Radial Artery Grafts Versus Saphenous Vein Grafts in Patients Undergoing Elective Coronary Artery Bypass Graft (CABG) Surgery…
Phase 2 N=389 Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery
Coronary Disease · Heart Diseases · Cardiovascular Diseases
Primary: Cognitive Function — 0.07; 0.12 Continuous cognitive change score
N/A N=54 Transitional Rehabilitation in CABG Patients
Coronary Artery Disease · Coronary Artery Bypass Graft Surgery
Primary: Short Physical Performance Battery — 7.33; 8.00; 11.44; 10.90 units on a scale
Phase 3 N=305 Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery
Diabetes
Primary: Number of Subjects That Were Diagnosed for Peri-operative Complications — 58; 70 participants
N/A N=156 Use of Intra-aortic Balloon Pump Before Surgery for Acute Myocardial Infarction
Acute Myocardial Infarction · Coronary Artery Disease · Coronary Bypass Graft Stenosis of Autologous Vessel
Primary: High-Sensitivity Cardiac Troponin Levels From Days 0-7 — 29.2; 17.3; 23.2; 16.7 ng/mL (0-0.04) — p=0.05
Phase 2 N=100 Quercetin in Coronary Artery By-pass Surgery
Coronary Artery Disease
Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
Phase 4 N=20 Reversing Ticagrelor's Effects With Fresh Platelets
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 284.1; 284.1; 39.1; 37.5 PRU
Phase 1 N=101 Cardiac Home Education and Support Trial (CHEST): A Pilot Study
Coronary Artery Disease
Primary: Health-related Quality of Life (SF-36v2-acute Form) — 72.6; 77.0; 60.4; 65.5 units on a scale — p=p<0.20
N/A N=1,500 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
Coronary Disease · Coronary Stenosis
Primary: MACCE — 80; 51 Participants — p=0.35
N/A N=160 The Effectiveness of a Telehealth Program on Cardiac Symptom Distress, Self-care and Quality of Life of Patients With Coronary Artery Disease After Coronary Artery Bypass Surgery: A Randomized Study
Telehealth · Coronary Artery Bypass Surgery
Primary: Cardiac Symptom Distress Score — 15.24; 12.84; 12.81; 11.87 scores on a scale
Phase 4 N=30 Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
Phase 3 N=314 Glutamate for Metabolic Intervention in Coronary Surgery II
Coronary Artery Bypass Surgery · Postoperative Complications · Heart Failure
Primary: Postoperative Increase of Plasma NT-proBNP — 5390; 6452 ng/L — p=0.086
N/A N=144 Coronary Artery Disease Screening in Kidney Transplant Candidates
End Stage Renal Disease · Coronary Artery Disease
Primary: Number of Participants Adhering to the Expected Number of Screening Tests — 59; 71 participants
Phase 4 N=250 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded
Phase 2 N=56 Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
Coronary Artery Bypass Grafting · Cardiopulmonary Bypass · Reperfusion Injury
Primary: Left Ventricular Stroke Work Index (LVSWI) — 42; 43; 29; 28 g*m/m2
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 4 N=84 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
Surgery · Coronary Artery Disease
Primary: Time to Extubation — 10.4; 6 Minutes
Phase 2 N=221 Maintenance of Platelet Inhibition With Cangrelor
Acute Coronary Syndrome (ACS)
Primary: Stage I: Percentage of Patient Samples That Maintained Platelet Inhibition Levels of Greater Than or Equal to 60% as Reported by the VerifyNow P2Y12 Point of Care Assay…
N/A N=1,024 Effect of an Educational Intervention on Cardiac Patients' Participation Rate in Cardiac Rehabilitation Programs
Coronary Artery Disease
Primary: Number of Patients Participating in Cardiac Rehabilitation Programs (CRPs)1-year Post Coronary Artery Bypass Grafting (CABG)Surgery in the Intervention and Control…
Phase 3 N=84 Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Coronary Artery Bypass
Primary: Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging — 14; 14 Participants — p=0.78